We began by analysing CRISPR-Cas9 screens used to identify genes that enhance or suppress sensitivity to a BRAF inhibitor (dabrafenib) in a partially-sensitive BRAF-mutant colorectal cancer cell line (HT-29) (Additional file 1: Fig. S6a). The gene discussed is BRAF; the disease is colorectal cancer.